Clinical trial
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
NCT02525822 is registered in ClinicalTrials.gov with Valeant Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
- Lead sponsor
- Valeant Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 30, 2015
- Completion date
- June 30, 2016
- Enrollment
- 210 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.